Larimar Therapeutics Inc LRMR Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jul 17, 2023 (filed on Jul 18, 2023)

Insider Name:

Clayton Russell

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

180,000

Price:

--
May 17, 2023 (filed on May 18, 2023)

Insider Name:

Celano Michael

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$3.73
May 17, 2023 (filed on May 18, 2023)

Insider Name:

Ben-Maimon Carole

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$3.71
May 17, 2023 (filed on May 18, 2023)

Insider Name:

Truitt Joseph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

2,750

Price:

$3.73
May 09, 2023 (filed on May 11, 2023)

Insider Name:

Flynn James E

Ownership Type:

Indirect Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,300

Price:

--
May 09, 2023 (filed on May 11, 2023)

Insider Name:

Truitt Joseph

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,300

Price:

--
May 09, 2023 (filed on May 11, 2023)

Insider Name:

Hamilton Thomas Edward

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,300

Price:

--
May 09, 2023 (filed on May 11, 2023)

Insider Name:

Leff Jonathan S

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,300

Price:

--
May 09, 2023 (filed on May 11, 2023)

Insider Name:

Thomas Frank E

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,300

Price:

--
Feb 07, 2023 (filed on Feb 09, 2023)

Insider Name:

Shankar Gopi

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

180,000

Price:

--

Filings by filing date

Jul 17, 2023 (filed on Jul 18, 2023)

Insider Name:

Clayton Russell

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

180,000

Price:

--
May 17, 2023 (filed on May 18, 2023)

Insider Name:

Celano Michael

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$3.73
May 17, 2023 (filed on May 18, 2023)

Insider Name:

Ben-Maimon Carole

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$3.71
May 17, 2023 (filed on May 18, 2023)

Insider Name:

Truitt Joseph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

2,750

Price:

$3.73
May 09, 2023 (filed on May 11, 2023)

Insider Name:

Flynn James E

Ownership Type:

Indirect Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,300

Price:

--
May 09, 2023 (filed on May 11, 2023)

Insider Name:

Truitt Joseph

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,300

Price:

--
May 09, 2023 (filed on May 11, 2023)

Insider Name:

Hamilton Thomas Edward

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,300

Price:

--
May 09, 2023 (filed on May 11, 2023)

Insider Name:

Leff Jonathan S

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,300

Price:

--
May 09, 2023 (filed on May 11, 2023)

Insider Name:

Thomas Frank E

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,300

Price:

--
Feb 07, 2023 (filed on Feb 09, 2023)

Insider Name:

Shankar Gopi

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

180,000

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Tel:	N/A
Website:	https://larimartx.com
IR:	See website

Key People

Carole S. Ben-Maimon President, Chief Executive Officer, Director	Michael Celano Chief Financial Officer, Company Secretary	Russell G. Clayton Chief Medical Officer
Gopi Shankar Chief Development Officer

Business Overview

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its cell penetrating peptide (CPP) technology platform. The Company's lead compound, CTI-1601, is being developed as a potential treatment for Friedreichs ataxia (FA). CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with FA. FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient frataxin (FXN) due to a genetic abnormality. It also focuses on using its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Its CPP platform enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets.

Financial Overview

For the six months ended 30 June 2023, Larimar Therapeutics Inc revenues was not reported. Net loss decreased 15% to $14.9M. Lower net loss reflects Other income, net increase from $36K (expense) to $2.4M (income), Research and Development decrease of 13% to $8.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.96 to -$0.34.

Employees:	26 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$59.17M as of Jun 30, 2023
Annual revenue (TTM):	$0.00M as of Jun 30, 2023
EBITDA (TTM):	-$35.83M as of Jun 30, 2023
Net annual income (TTM):	-$32.64M as of Jun 30, 2023
Free cash flow (TTM):	-$27.47M as of Jun 30, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	43,277,500 as of Aug 7, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization